

Swiss Oncology & Hematology Congress 2022
Basel, Switzerland



Clinical value of biomarkers in **Gastric** and **GEJ** Cancers

PD-L1

MSI

CLDN18.2

FGFR2b

HER2

**Satellite
Symposium**

Thursday,
17th November 2022,

12:15–13:15 h

Room
Shanghai 3–4

GEJ, gastro-oesophageal junction; CLDN18.2, claudin 18.2; FGFR2b, fibroblast growth factor receptor 2b; HER2, human epidermal growth factor receptor 2; MSI, microsatellite instability; PD-L1, programmed cell death-ligand 1

Timing	Session	Speaker
12:15h	Welcome and introduction	Dr. Alexander Siebenhüner
12:20h	An overview of unresectable locally advanced or metastatic G/GEJ adenocarcinoma & current approach to treatment in Switzerland	Dr. Alexander Siebenhüner
12:30h	Biomarker testing in unresectable locally advanced or metastatic G/GEJ adenocarcinoma	Univ.-Prof. Dr. Rupert Langer
12:45h	Emerging treatments for unresectable locally advanced or metastatic G/GEJ adenocarcinoma	Dr. Thibaud Kössler
13:00h	Working together in an evolving therapeutic landscape	All
13:10h	Q&A session, meeting summary and close	All/Chair

The faculty



Chair:
Dr. Alexander Siebenhüner
Head Physician Clinic for
Internal Medicine, Oncology
Kantonsspital Schaffhausen,
Switzerland



Univ.-Prof. Dr. Rupert Langer
Director of the Clinical Institute
of Pathology and Molecular
Pathology
Kepler Universitätsklinikum Linz,
Austria



Dr. Thibaud Kössler
Oncology Department Head of
the Digestive Tumors Unit
Hôpitaux Universitaires Genève,
Switzerland

This invitation is intended for healthcare professionals. This non-promotional symposium is solely organized and funded by Astellas Pharma AG, Switzerland

Astellas Pharma AG | Richtring 28 | 8304 Wallisellen | Switzerland
www.astellas.ch
MA-MM-00028 | Date of preparation: September 2022

